Elotuzumab works by engaging both the cancer cells and the immune system. It binds to the SLAMF7 protein on myeloma cells, making them more visible to the body's immune system. At the same time, it activates natural killer (NK) cells, which are a type of white blood cell that can destroy cancer cells. This dual action helps in enhancing the immune response against the cancer cells.
